ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Wyeth has licensed Inovio Biomedical's DNA delivery technology for vaccines for an up-front fee of $4.5 million. Wyeth will also pay undisclosed license maintenance fees, research support payments, and up to $60 million in milestone payments. Inovio says its MedPulser electroporation technology has been shown in primate studies to sharply boost the immune response to DNA vaccines compared with the response to DNA plasmid delivered via standard injection.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter